



PERIMETER

Imaging Like You've Never Seen Before

Weekly IR Round-Up

New White Paper Outlines Significant Impact of Reoperations for Breast-Conserving Surgeries

Perimeter's [new White Paper](#) highlights the full impact of reoperations for breast-conserving surgeries, including harmful effects on patients, strain of healthcare resources, and heightened costs.

Using Perimeter S-Series OCT, a non-invasive imaging technique, has the potential to provide surgeons insights on margins during surgery, in efforts to reduce the likelihood of leaving cancerous cells behind. Read [full paper here](#).

New white paper Reoperation Realities in Breast Cancer Care



PERIMETER

#ICYMI (In Case You Missed It)

Perimeter issued a [news release](#) and hosted a webcast yesterday to report its fourth quarter/year-end 2023 results. If you didn't dial in live, you can still listen to the call.



Q4 2023 Conference Call

Thursday, March 28

4:30 p.m. ET

[Replay is available here](#)

"This is an exciting time at Perimeter, as we solidify our position in our first market, expand our product portfolio, and explore opportunities for market expansion, including additional cancer indications."

-Adrian Mendes

Perimeter's Chief Executive Officer

"As we enter 2024, patient enrollment is outpacing our original projections for our pivotal clinical trial. We continue to execute on our go-to-market strategy to 'seed the market' by adding surgeon champions and reference sites for our S-Series OCT technology, in support of our goal to broaden the user base after our proprietary AI is approved in a breast cancer indication. In addition, our pipeline of product innovations is growing, with several new product introductions and AI enhancements anticipated this year."

Let's Stay Connected

Follow Perimeter Medical on Social!

The best way to hear the latest news from Perimeter is to follow us on one of our social media channels:

- **X** (formerly Twitter): <https://twitter.com/PerimeterMed>
- **LinkedIn**: <https://www.linkedin.com/company/perimeter-medical-imaging/>

You can also sign up to get Perimeter [news release alerts](#) delivered directly to your email or check out the news feed on our [investor website](#).

Perimeter S-Series OCT has 510(k) clearance under a general indication and has not been evaluated by the U.S. FDA specifically for use in breast tissue, breast cancer, other types of cancer, margin evaluation, and reducing re-excision rates. The safety and effectiveness of these uses has not been established. For more information, please visit www.perimetermed.com/disclosures.

For more information about Perimeter, please contact: investors@perimetermed.com



Perimeter Medical Imaging AI, 8585 N. Stemmons Freeway, Suite 106N, Dallas, TX 75247

[Unsubscribe Preferences](#)

[TSXV: PINK](#) | [OTC PYNKF](#) | [FSE: 4PC](#)



© 2024 Perimeter Medical Imaging AI, Inc.